Multiomics Analysis Reveals Molecular Pathways Associated With the Effects of Pinus Massoniana Needles Extract on Androgenetic Alopecia

In this study, researchers discovered a compound called C6 that exhibits excellent skin retention and androgen receptor degradation properties, significantly promoting hair regeneration in a mouse model of androgenetic alopecia following non-invasive topical application, suggesting potential for broader use of PROTACs in treating skin diseases.

This study developed caffeine-loaded nanoparticles coated with ultradeformable liposomes for better hair follicle delivery, showing non-cytotoxicity and potential to reduce oxidative stress in DHT-damaged cells, suggesting an alternative treatment for androgenetic alopecia.

This study used a mouse model to enhance understanding of alopecia pathogenesis and suggested a therapeutic strategy for managing inflammation in EGFR-inhibitor therapy-induced folliculitis and cicatricial alopecia.

Combining PRP, microneedling, and minoxidil may improve hair regrowth in severe hair loss cases.

This study found that dissolving microneedles loaded with platinum nanozymes induced faster hair growth in an androgenetic alopecia model than daily minoxidil applications, with no significant safety concerns.

This review discusses the current state of alopecia areata treatments, noting that while recent advances such as Janus Kinase inhibitors show promise, persistent challenges like limited efficacy, safety concerns, and patient compliance highlight the need for innovative drug discovery and development strategies.

Switching JAK inhibitors or using dupilumab may help some alopecia areata patients who don't respond well to initial treatments.

This study identified Th22 cells as key effectors in hair regeneration driven by thymosin beta 15, suggesting they could be potential targets for hair regrowth therapies.

This study found that patients with alopecia areata and their healthy family members had elevated levels of Th1- and Th17-related cytokines, suggesting a genetic link in cytokine dysregulation.

This comprehensive review analyzes androgenetic alopecia treatments, discussing the mechanisms, costs, efficacy, and safety of FDA-approved drugs like minoxidil and finasteride, as well as newer non-FDA-approved options that have shown effectiveness across various studies.

This review discusses psychological treatments for alopecia, finding limited but positive effects on mental health, quality of life, and possibly hair growth; however, more research is needed to establish intervention efficacy.

The researchers reported that a 5% Beta vulgaris L. extract nanogel showed better antialopecic activity in testosterone-induced alopecia in mice compared to a 2.5% concentration.

This review discusses treatment options for androgenetic alopecia, highlighting the need for personalized, evidence-based approaches but reports no new clinical results.

This review evaluates laboratory models used in androgenetic alopecia research but reports no new findings, emphasizing the potential of human-derived 3-D models for future studies.

This study found that dihydrotestosterone induced hair loss and changes in hair morphology in male C57BL/6 mice, effects that could be partially reversed by the AR antagonist bicalutamide.

This review describes the molecular interactions between androgens and Wnt/ß-catenin signaling in androgenetic alopecia but reports no new experimental or clinical findings; the authors discuss potential Wnt/ß-catenin-targeted treatments for hair growth.

This study found that finasteride was associated with more reproductive adverse effects, including sexual dysfunction in men and fetal harm in women, compared to minoxidil in reported alopecia cases.

This review discusses the steroidogenic properties of human skin and suggests that impaired steroidogenesis may be linked to conditions like acne, rosacea, atopic dermatitis, and androgenic alopecia, but reports no new clinical results.

This review discusses current therapeutic targets and treatments for androgenic alopecia but reports no clinical results; the authors highlight the challenge of developing multi-target drugs for effective treatment.

This study found that subcutaneous testosterone therapy improved scalp hair growth in a majority of androgen-deficient women who previously reported hair thinning and did not report hair loss as a side effect.

This study reports that in primary cicatricial alopecias, increased expression of certain immune markers in the hair-follicle bulge suggests a collapse of immune privilege, which may contribute to follicle destruction.

In this study, thymosin beta4 was found to stimulate hair growth in normal rats and mice by affecting key processes in the hair follicle cycle, such as stem cell migration and extracellular matrix remodeling.